AI MARKET SCANNING

ALX Oncology Holdings Inc.

📅 Next Catalyst: Nov 06, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -1.63%
MAX GAP RECORD -13.05%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ALXO
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 06, 2026 Earnings Release 2026-11-06 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
+1.04%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
+0.00%
Feb 27, 2026 Earnings Release 2026-02-27 (BEFORE OPEN)
-8.94%
Nov 07, 2025 Earnings Release 2025-11-07 (BEFORE OPEN)
+2.54%
Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE)
+0.81%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
-0.79%
Mar 06, 2025 Earnings Release 2025-03-06 (AFTER CLOSE)
-4.58%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.0%
Bullish Gaps (6)
Bearish Gaps (6)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ALXO

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗